Butyrate supplements

Butyrate is a short-chain fatty acid that gut bacteria produce when they ferment fiber. Some studies of microencapsulated sodium butyrate alongside standard treatment in adults with ulcerative colitis have reported interesting clinical results. Those findings do not automatically apply to other products, healthy people, or children: a pediatric trial found no additional benefit. Tributyrin is a different chemical form, but the studies cited here do not establish its superiority over sodium butyrate in humans. Fermentable fiber remains an important way to support butyrate production in the gut.

Butyrate, tributyrin, and sodium butyrate in plain language

Butyrate is a four-carbon short-chain fatty acid, or SCFA. It is a major energy source for the cells lining the colon. Gut bacteria produce it by fermenting fiber; microbial fermentation is the principal source of butyrate within the colon. It is also sold as an oral supplement in several salt and ester forms. Source 1

The SCFA family includes acetate, propionate, and butyrate, all produced through fermentation in the colon. Colonocytes, the cells lining the colon, preferentially use butyrate as fuel; the other two are absorbed and used elsewhere in the body. For supplementation, the important questions concern the formulation, the evidence behind it, and whether it offers more than the butyrate generated from dietary fiber in the gut.

Chemistry and structure: what an ester changes

Butyric acid (CH₃CH₂CH₂COOH) is a saturated four-carbon carboxylic acid with a characteristic smell reminiscent of rancid butter. With supplements, coating and formulation also influence odor. Tributyrin is glyceryl tributyrate: three butyrate groups attached to a glycerol backbone. Lipases can break these ester bonds and release butyrate. Where and to what extent that happens must be tested for the particular formulation. Two frequently cited sources do not answer this question for human supplements. The nanoemulsion paper studies a cancer-drug formulation containing 5-fluorouracil and short-chain triglycerides; the capsule paper studies protection of pancreatin in the laboratory. In the latter, tributyrin conversion is an enzyme-activity assay, not evidence of superior butyrate delivery to the human colon. Source 1 Source 2

From research on colon cells to supplements

In 1980, William Roediger published foundational work proposing that impaired butyrate utilization could contribute to an energy deficit in the colonic epithelium in ulcerative colitis. Related work examined the importance of butyrate from anaerobic bacteria to human colonic mucosal metabolism. These studies helped shape subsequent research into gut physiology and inflammatory bowel disease, or IBD. Animal nutrition research also investigated dietary tributyrin, including experiments in pigs with intestinal injury and colitis. Encapsulated formulations were explored as a way to alter exposure. This research connects intestinal physiology, disease models, and today’s supplement products, but does not make them interchangeable. Microbial fermentation remains the principal source of colonic butyrate. Supplementation is one proposed way to address altered availability; it is not proof that everyone with a changed microbiome has a deficiency requiring treatment. Source 1 Source 2 Source 3 Source 4

How butyrate fuels colon cells and affects gene activity

Two important mechanisms help explain interest in butyrate. First, it serves as a preferred fuel for colonocytes and contributes to the environment supporting the intestinal barrier. Second, it can act as an epigenetic regulator by inhibiting histone deacetylases, or HDACs, enzymes involved in controlling gene activity. Both mechanisms have implications for research on the gut and the rest of the body.

Two mechanisms, one molecule

Colonocytes use butyrate as an important energy source, including through beta-oxidation. This energy supply supports tight junctions, the close connections between cells, and mucosal integrity. Changes in butyrate availability can affect the epithelial barrier, with effects depending on the biological context. Its role in maintaining the colonic epithelium has been studied in several model systems. Research has also examined anti-inflammatory effects of SCFAs on inflamed colonic tissue through energy-related pathways. These biological functions help explain why supplementation is studied, without establishing the effect of any particular capsule. Source 1 Source 2

The second mechanism operates at the level of gene expression. Butyrate can inhibit HDAC activity, changing chromatin organization and transcription. These epigenetic effects are considered one explanation for its inflammation-related actions in experimental systems. Butyrate has also been linked to regulatory T-cell induction and modulation of interleukin-10 in the colonic mucosa. Microbiota-derived SCFAs can influence inflammatory pathways through overlapping immune, metabolic, and epigenetic mechanisms that researchers are still characterizing. Findings from these systems should not be read as proof of a clinical effect at an arbitrary supplement dose. Source 1 Source 2 Source 3

Why the release formulation matters

Butyrate can be absorbed in the upper digestive tract. Coatings, encapsulation matrices, and ester forms are intended to alter release, but a chemical name alone does not tell us how much reaches the colon. Tributyrin is a lipase substrate, and pig studies offer clues about possible intestinal effects. They do not measure superiority over microencapsulated sodium butyrate in humans. The cited nanoemulsion and pancreatin-capsule studies are not such comparisons either. Rapid utilization of absorbed butyrate also makes it difficult to infer the concentration at a target site from the amount swallowed. Data on the actual product matter more than assuming that salt forms never reach the colon and tributyrin always does. Source 1 Source 2 Source 3

Which effects are supported by studies?

The evidence for butyrate supplementation is uneven. IBD research includes some of the most informative human data. Claims about systemic metabolic effects, intestinal permeability, or tributyrin’s superiority over sodium butyrate have a thinner foundation. Each proposed effect therefore needs its own assessment.

The following terms describe the kinds of evidence available. They are not a formal GRADE assessment or a statement of regulatory approval:

• Strong: Consistent results from several well-conducted human studies with clinically relevant outcomes. A large sample alone does not eliminate bias.

• Moderate: Clinical data exist, but precision, comparability, duration, or applicability remains limited. A single positive trial does not establish a general recommendation.

• Limited: Small, short, or methodologically constrained human studies, or observational findings with substantial uncertainty.

• Preclinical: Cell, tissue, or animal models. Human phase I studies are a separate category; they often initially examine safety and pharmacokinetics rather than an established clinical benefit.

• Anecdotal: Case reports or experiences without a controlled comparison. Mechanistic plausibility is a different type of evidence and is identified as such.

Microencapsulated sodium butyrate in ulcerative colitis: distinguish positive and negative trials

A multicenter trial in 98 adults with active mild-to-moderate ulcerative colitis tested 600 mg of microencapsulated sodium butyrate daily for eight weeks alongside standard treatment. It reported improvements in clinical, endoscopic, and biochemical outcomes. Another randomized trial in 140 people with IBD examined microbiota, disease activity, and quality of life; results varied by disease and microbiota profile. The reduction in calprotectin in ulcerative colitis was not statistically significant in that study, with p=0.09. A small study involving 36 participants with active ulcerative colitis also reported favorable findings, but its dose reporting needs clarification and does not provide a dosing recommendation here. The pediatric trial had a different result: among 72 children and adolescents completing twelve weeks, additional sodium butyrate offered no advantage over placebo in remission or disease activity. These trials support further formulation-specific research, not replacement of standard IBD treatment. Source 1 Source 2 Source 3 Source 4

The intestinal barrier and permeability: plausible mechanisms, limited clinical evidence

There is a substantial mechanistic rationale. Butyrate contributes to the maintenance of the colonic epithelium in ways that support tight-junction integrity. The gap concerns direct human supplementation trials with permeability as the primary outcome; such studies are uncommon. Preclinical tributyrin research has shown protective intestinal effects in stressed animal models. Another cited paper investigated growth and intestinal health in green mud crabs, which is also not a human finding. These experiments provide biological clues, but cannot establish an effect on human intestinal permeability from a supplement. Source 1 Source 2 Source 3

Does tributyrin deliver butyrate more effectively than sodium butyrate?

An in vitro study of tributyrin (CoreBiome) examined simulated digestion, microbiota, and barrier and immune responses, reporting favorable changes. That is a preclinical observation, not direct evidence of better delivery or treatment in people. The cited nanoemulsion work concerns co-delivery of 5-fluorouracil and short-chain triglycerides; the capsule study protects pancreatin and uses tributyrin as a test substrate. Neither can be read as a clinical comparison of tributyrin and sodium butyrate. A reliable ranking would require direct studies of specific formulations, including release, concentrations at the target site, and clinical outcomes. Source 1 Source 2 Source 3

Metabolism, systemic inflammation, and the blood-brain barrier: largely preclinical foundations

Reviews of butyrate’s proposed protective role in obesity and diabetes draw mainly on animal experiments and mechanistic data. Protection of the blood-brain barrier by microbiota-derived SCFAs, including butyrate, is described mechanistically rather than established clinically. Its possible role in neurodegenerative disease is another area of emerging preclinical research. These papers do not establish clinical recommendations. They show that systemic effects are biologically plausible, without demonstrating the proposed benefits in humans. Source 1 Source 2 Source 3

The evidence discussed here does not establish a cure for IBD or a replacement for standard treatment. It also does not establish a general disease-modifying effect in IBS, so-called leaky gut syndrome, or metabolic and neurodegenerative diseases. Positive add-on trials in selected patients with IBD remain relevant nonetheless. Selling a supplement is not the same as holding a drug approval for these indications.

Forms and bioavailability: why release matters

Not all products are equivalent. Salt or ester form, coating, other ingredients, and release behavior can alter exposure. Without product-specific data, these differences do not establish a universal ranking. Neither “microencapsulated” nor “tributyrin” alone guarantees a particular butyrate concentration in the colon.

• Uncoated sodium butyrate: The sodium salt of butyric acid. Amount and formulation vary; the mass of the salt is not the same as the mass of pure butyric acid. Odor may make it harder to take consistently. How much reaches a particular intestinal segment needs to be assessed for the product. The cited pancreatin-capsule paper provides no direct evidence for that question. Source 1

• Microencapsulated sodium butyrate: A matrix is intended to alter release. This product category has been tested in clinical IBD trials, with positive findings in selected adults and no additional efficacy in the cited pediatric study. A certificate of analysis can check content claims but does not automatically confirm release in the human colon. Source 1 Source 2

• Calcium and magnesium butyrate: Other mineral salts that provide the respective mineral as well as butyrate. The salt name alone does not establish pharmacokinetics identical to sodium butyrate. Coating, quantity, and particular limitations, such as those associated with kidney disease, remain relevant.

• Tributyrin: A glycerol ester from which lipases can release butyrate. Preclinical studies show interesting intestinal effects, but do not demonstrate generally better delivery to the human colon. Labels should distinguish tributyrin mass from a theoretical butyrate equivalent; neither establishes the amount actually released at the target site. Source 1 Source 2

• Fermentable fiber: Resistant starch and inulin are examples of substrates for microbial fermentation. Psyllium works partly through gel formation and is not interchangeable in every respect with highly fermentable fibers. The SCFAs produced depend on the fiber and microbiota. Fiber is not a preformed butyrate supplement.

Independent quality testing may cover identity, content, selected contaminants, or manufacturing conditions, depending on the program. A certification needs to be verified for the particular product and its actual scope. It demonstrates neither a clinical effect nor special release in the colon. A batch-specific certificate of analysis can be useful, but should identify methods and the salt or ester measured. The studies cited here do not establish how many butyrate products currently hold independent certification.

Useful label information includes the exact salt or ester form, the amount per serving, and the actual tributyrin content of tributyrin products. A vague term such as “butyrate complex” makes comparison difficult; it does not, by itself, prove adulteration. Claimed enteric release should also be supported by data on the particular formulation.

Regulatory status and product claims

Butyrate products are sold in categories including dietary supplements. In the United States, the FDA does not review and approve dietary supplements for safety and effectiveness before sale in the way it does drugs. Statements about supporting normal body function are not FDA endorsements. A product marketed to treat, prevent, or cure a particular disease may fall under drug regulation. Availability therefore does not establish an approved IBD treatment. Source 1

Legal classification can differ by country, product, and purpose. Terms such as “pharmaceutical grade,” microspheres, or enteric-coated capsules do not replace verification of a specific authorization. Nor can a blanket anti-doping clearance be inferred from the ingredient name: competitive athletes need to consider the actual product, possible contamination, and current rules. Quality testing applies to its stated scope and is not a guarantee against every risk.

Safety, side effects, and drug interactions

Short-term studies provide some information about tolerance of individual formulations. They are insufficient to define rare adverse effects or the long-term safety of every butyrate product. Odor and gastrointestinal tolerance can influence practical use, but their frequency should not be stated without suitable study data.

What the IBD studies documented

The pediatric IBD trial reported no adverse events among its 72 completers. It therefore did not document the frequent gastrointestinal adverse effects previously attributed to it. For other trials too, claims about bloating, stool consistency, or headaches need to come from the safety findings actually reported. A rancid-butter smell may have a chemical explanation, but establishes neither toxicity nor product purity. Pig studies of tributyrin and human studies of sodium butyrate involve different exposures. Together, they do not provide a comprehensive safety profile for long-term tributyrin supplementation in people. Source 1 Source 2 Source 3 Source 4 Source 5 Source 6

Interaction data are limited

• 5-ASA and other IBD treatments: Some trials added butyrate to standard treatment. They provide information about the combinations studied, not a blanket classification of all interactions as minor or safely additive. Source 1 Source 2

• Proton pump inhibitors and motility medicines: Changes in pH and transit may matter for release formulations. Reliable direct data on a particular clinical interaction are lacking here, so “minor” would not be an established rating.

• Antibiotics: They can alter the microorganisms that produce butyrate. That raises a research question, but does not establish a general recommendation for butyrate during or after antibiotics.

Evidence on butyrate-specific interactions is limited. For people taking several medicines or living with complex gastrointestinal disease, the full medication list and exact formulation matter more than general reassurance. Laboratory tests are needed only when there is an appropriate clinical question.

Pregnancy, breastfeeding, and groups needing particular consideration

Pregnancy and breastfeeding: Adequate controlled safety data on additional supplements are lacking here, so independent use is not a sensible choice. Liver disease: Altered metabolism is theoretically possible, but appropriate dosing data are missing. Kidney disease: Additional sodium, magnesium, or calcium needs to be considered according to the salt form. An active IBD flare: Supplementation must not delay standard assessment and treatment. Children and adolescents: The cited controlled trial found no additional clinical benefit; its limited follow-up is not a general demonstration of long-term safety either. Source 1

When a butyrate supplement is the wrong first step

For unexplained or severe symptoms, a supplement is not the right starting point. The practical concern is particularly the possibility of postponing a necessary assessment in favor of self-treatment.

• Pregnancy or breastfeeding: controlled human safety data for supplemental doses are lacking.

• Active untreated IBD or persistent unexplained gastrointestinal symptoms: seek assessment first rather than delaying standard investigation through supplementation.

• Severe kidney or liver impairment: safety data are limited, and additional sodium and magnesium need to be considered according to the salt form.

• Severe immunosuppression: data are limited; discuss use with the gastroenterology team beforehand.

• Known hypersensitivity to an ingredient or excipient in the particular product.

• Children and adolescents: the available pediatric IBD study does not justify a general supplementation recommendation.

If any of these apply, discuss supplementation with a clinician first. The complete medication list and any existing relevant laboratory results help inform that conversation.

Butyrate supplements versus production from dietary fiber

For most people, the practical question is whether taking preformed butyrate offers more than providing substrate for the gut bacteria that naturally produce it. The answer depends on the purpose, the condition being considered, and the evidence for the particular intervention.

• Source and chemistry: A supplement provides a preformed butyrate compound. Fermentable fiber provides substrate for gut microorganisms. Several bacterial groups and their metabolic interactions influence which SCFAs are produced; not every fermenting species is a direct butyrate producer.

• Release: With supplements, this depends on formulation and digestion. Fiber fermentation generates SCFAs in the gut, but quantity and composition vary. The cited pancreatin-capsule study is not a direct human comparison of tributyrin, sodium butyrate, and fiber. Source 1

• Clinical data: Particular sodium-butyrate formulations have positive add-on trials in adults with IBD. Results are not uniformly positive and cannot be transferred to every form. Fiber has been studied for bowel function and various metabolic outcomes; that does not mean every fiber has the same effect in every setting. Source 1 Source 2

• Amounts studied: The cited adult ulcerative-colitis trial used 600 mg of sodium butyrate daily for eight weeks; the pediatric trial used 150 mg twice daily for twelve weeks without additional benefit. These are study protocols, not a general dose recommendation. Fiber quantities likewise need to suit the particular fiber, overall diet, and tolerance.

• Tolerance: Products differ in excipients, mineral content, and odor. Fermentable fibers can cause gas; highly fermentable products such as inulin are not always well tolerated by people with sensitive bowels. The amount and type of fiber therefore matter.

• Cost: This depends on the product, amount, and country. Fiber-rich foods and isolated fiber supplements are different options; neither is universally free.

• Regulation: Fiber may be part of an ordinary food or a supplement. In the United States, a dietary supplement does not receive premarket efficacy approval in the way a drug does. The actual product category and marketing claims remain important.

For general bowel function, a suitable, well-tolerated diet is usually a more useful starting point than looking for a supposedly best form of butyrate. In diagnosed IBD, a particular microencapsulated sodium-butyrate formulation may be discussed as an add-on with the treating clinician; the clinical findings must not automatically be extended to tributyrin. Diet and a possible supplement address different questions. Whether laboratory tests are useful, and which ones, should follow the condition being managed rather than a universal supplement protocol.

What measurements can and cannot tell us about butyrate

Blood and stool measurements reflect different processes. An inflammatory marker may describe a disease without specifically measuring the effect of butyrate. A change after starting a product does not, by itself, establish cause and effect either.

• hs-CRP: A nonspecific marker of systemic inflammation. HDAC mechanisms do not allow us to predict a reliable reduction or a fixed timeline of eight to twelve weeks.

• HbA1c: Reflects longer-term blood glucose. It can be useful for an appropriate metabolic question, but is not an established general test of butyrate effectiveness.

• Fasting insulin: May be interpreted in selected situations, but does not by itself provide a comprehensive measurement of insulin sensitivity. Routine testing before butyrate is not justified by the studies cited here.

• Fecal calprotectin: Can help assess intestinal inflammation and its course in IBD. It has also been measured in butyrate trials, but does not specifically identify which component of a combined treatment caused a change. Source 1 Source 2

• Stool butyrate or an SCFA panel: Measures concentration in the stool sample, not directly the production rate in the colon. Absorption, utilization, transit, and water content affect the result. A low single measurement therefore does not establish a butyrate deficiency requiring treatment.

These findings do not establish a general recommendation for baseline hs-CRP, HbA1c, and fasting-insulin testing before butyrate supplementation. In IBD, appropriate monitoring may be useful within the existing treatment plan. Even with a baseline, natural variation, other treatments, and regression to the mean remain possible explanations for a change. Controlled comparisons are essential to establish effectiveness.

Which intestinal symptoms need medical assessment?

Persistent diarrhea, rectal bleeding, unintentional weight loss, or severe abdominal pain cannot be diagnosed as a butyrate deficiency. They need medical assessment so that IBD or another condition requiring treatment is not overlooked. The necessary investigations depend on symptoms and examination findings. Calprotectin or blood markers may be part of that assessment, but are not a preliminary self-testing protocol for buying a supplement.

Frequently asked questions

What is a butyrate supplement?

A butyrate supplement provides a compound of the short-chain fatty acid butyrate, which colon cells use as an important energy source. Gut bacteria produce butyrate from fermentable substrates. Supplements may contain sodium, calcium, or magnesium butyrate, or the ester tributyrin. Chemical form and formulation influence release, but do not establish a universal advantage for tributyrin in the human colon.

Do butyrate supplements actually work?

Some trials in adults with ulcerative colitis reported favorable findings for particular sodium-butyrate formulations alongside standard treatment. The pediatric study, in contrast, found no additional benefit after twelve weeks. Mechanisms such as HDAC inhibition explain the research interest but do not establish an individual’s treatment response. IBD findings do not automatically apply to healthy adults or other formulations. Fermentable fiber remains a reasonable dietary approach, adjusted to tolerance. Source 1 Source 2 Source 3

What butyrate dose has been used in studies?

One adult ulcerative-colitis trial used 600 mg of microencapsulated sodium butyrate daily for eight weeks. The pediatric study tested 150 mg twice daily for twelve weeks and found no added benefit. These amounts describe specific experiments, not recommended self-treatment or an interchangeable dose range for tributyrin. Source 1

What are the side effects of butyrate supplements?

Gastrointestinal symptoms or intolerance can occur, but the cited studies do not justify labeling them universally common. The pediatric study reported no adverse events. The characteristic odor can make a product harder to take consistently. Data are insufficient for rare adverse effects, long-term use, and the full range of commercial products.

Are butyrate supplements FDA-approved?

Products marketed as dietary supplements in the United States are not approved for safety and effectiveness before sale in the same way as drugs. Such marketing is not FDA confirmation of an effect against IBD. Legal assessment depends on the specific product and its claims; statements about treating disease face different requirements from statements about normal body function.

Should I take a butyrate supplement or eat more fermentable fiber?

For general nutrition, an appropriate fiber intake is a sensible starting point. Type and quantity should suit tolerance; individualized dietary advice may help in IBD or when symptoms are pronounced. Low fiber intake or a single stool-SCFA result does not establish a need for a butyrate product. Supplementation should address a clearly stated question rather than automatically treat presumed underproduction.

Who should avoid butyrate supplements?

Independent supplementation is not a sensible approach during pregnancy or breastfeeding, with significant liver or kidney disease, when taking multiple medicines, or in children. Interaction data are limited; “minimal” or “minor” would not be reliable reassurance without appropriate research. Known reactions to product ingredients and persistent unexplained intestinal symptoms should be discussed medically before use.

Which blood tests should I have before trying butyrate?

There is no generally recommended blood panel before trying butyrate. hs-CRP, HbA1c, and insulin do not specifically measure a butyrate effect. In diagnosed IBD, fecal calprotectin may be part of clinician-led monitoring. Investigations should follow the actual disease or diagnostic question, rather than the purchase of a supplement.

References

• Roediger WE (1980). The colonic epithelium in ulcerative colitis: an energy-deficiency disease?. Lancet (London, England), 2(8197), 712-5. 91934-0). https://doi.org/10.1016/s0140-6736(80)91934-0

• Fukumori C, Branco PC, Barreto T, Ishida K, Lopes LB (2023). Development and cytotoxicity evaluation of multiple nanoemulsions for oral co-delivery of 5-fluorouracil and short chain triglycerides for colorectal cancer. European journal of pharmaceutical sciences, 187, 106465. https://doi.org/10.1016/j.ejps.2023.106465

• Karimian Azari E, Govaert M, Duysburgh C, Glab S, Marzorati M, Saiyed Z (2026). Evaluation of Targeted-Release Capsule Formulations for Protection of the Acid-Sensitive Enzyme Pancreatin Under Fasted and Fed Intestinal Conditions In Vitro. Pharmaceutics, 18(3). https://doi.org/10.3390/pharmaceutics18030285

• Roediger WE (1980). Role of anaerobic bacteria in the metabolic welfare of the colonic mucosa in man. Gut, 21(9), 793-8. https://doi.org/10.1136/gut.21.9.793

• Hou Y, et al. (2014). Dietary supplementation with tributyrin alleviates intestinal injury in piglets challenged with intrarectal administration of acetic acid. British journal of nutrition, 111(10), 1748-58. https://doi.org/10.1017/S0007114514000038

• Sommer KM, et al. (2022). Oral gamma-cyclodextrin-encapsulated tributyrin supplementation in young pigs with experimentally induced colitis. Journal of animal science, 100(11). https://doi.org/10.1093/jas/skac314

• Fagundes RR, et al. (2024). Beyond butyrate: microbial fiber metabolism supporting colonic epithelial homeostasis. Trends in microbiology, 32(2), 178-189. https://doi.org/10.1016/j.tim.2023.07.014

• Scheppach W, et al. (1997). Effects of short-chain fatty acids on the inflamed colonic mucosa. Scandinavian journal of gastroenterology. Supplement, 222, 53-7. https://doi.org/10.1080/00365521.1997.11720719

• Stein RA, Riber L (2023). Epigenetic effects of short-chain fatty acids from the large intestine on host cells. microLife, 4, uqad032. https://doi.org/10.1093/femsml/uqad032

• Ottria R, et al. (2026). Gut Microbiota-Derived Short-Chain Fatty Acids in Inflammatory Bowel Disease. International journal of molecular sciences, 27(2). https://doi.org/10.3390/ijms27021095

• Abdelhalim KA (2024). Short-chain fatty acids (SCFAs) from gastrointestinal disorders, metabolism, epigenetics, central nervous system to cancer. Chemico-biological interactions, 388, 110851. https://doi.org/10.1016/j.cbi.2023.110851

• Karłowicz K, et al. (2025). Efficacy of Microencapsulated Sodium Butyrate as Add-On Therapy in Inducing Remission in Patients with Mild-To-Moderate Ulcerative Colitis. Medical science monitor, 31, e948912. https://doi.org/10.12659/MSM.948912

• Facchin S, et al. (2026). Impact of oral butyrate on clinical and biochemical parameters in IBD. Digestive and liver disease, 58(1), 64-73. https://doi.org/10.1016/j.dld.2025.11.014

• Firoozi D, et al. (2025). Effects of Short Chain Fatty Acid-Butyrate Supplementation on the Disease Severity, Inflammation, and Psychological Factors in Patients With Active Ulcerative Colitis. Journal of nutrition and metabolism, 2025, 3165876. https://doi.org/10.1155/jnme/3165876

• Pietrzak A, et al. (2022). Sodium Butyrate Effectiveness in Children and Adolescents with Newly Diagnosed Inflammatory Bowel Diseases. Nutrients, 14(16). https://doi.org/10.3390/nu14163283

• Peng H, et al. (2026). Tributyrin enhances growth and intestinal health in green mud crab. Animal nutrition, 24, 266-277. https://doi.org/10.1016/j.aninu.2025.06.013

• Duysburgh C, et al. (2025). Tributyrin (CoreBiome). Frontiers in nutrition, 12, 1712993. https://doi.org/10.3389/fnut.2025.1712993

• Mayorga-Ramos A, et al. (2022). Protective role of butyrate in obesity and diabetes: New insights. Frontiers in nutrition, 9, 1067647. https://doi.org/10.3389/fnut.2022.1067647

• Fock E, Parnova R (2023). Mechanisms of Blood-Brain Barrier Protection by Microbiota-Derived Short-Chain Fatty Acids. Cells, 12(4). https://doi.org/10.3390/cells12040657

• Chakraborty P, et al. (2024). Butyrate as a potential therapeutic agent for neurodegenerative disorders. Neurochemistry international, 176, 105745. https://doi.org/10.1016/j.neuint.2024.105745